Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

AMPE | Ampio Pharmaceuticals Inc

Index- P/E- EPS (ttm)-19.03 Insider Own9.68% Shs Outstand0.76M Perf Week-13.68%
Market Cap3.07M Forward P/E- EPS next Y-24.00 Insider Trans433.27% Shs Float0.68M Perf Month3.06%
Income-13.98M PEG- EPS next Q-0.02 Inst Own3.14% Short Float / Ratio3.13% / 0.67 Perf Quarter-12.78%
Sales0.00M P/S- EPS this Y20.00% Inst Trans- Short Interest0.02M Perf Half Y-19.20%
Book/sh8.69 P/B0.47 EPS next Y0.00% ROA-76.89% Target Price- Perf Year-82.76%
Cash/sh9.14 P/C0.44 EPS next 5Y- ROE-104.89% 52W Range3.35 - 23.73 Perf YTD-10.30%
Dividend- P/FCF- EPS past 5Y34.16% ROI-210.10% 52W High-82.98% Beta1.73
Dividend %- Quick Ratio3.67 Sales past 5Y0.00% Gross Margin- 52W Low20.45% ATR0.45
Employees13 Current Ratio3.67 Sales Q/Q- Oper. Margin0.00% RSI (14)46.56 Volatility11.42% 12.23%
OptionableNo Debt/Eq0.07 EPS Q/Q33.89% Profit Margin- Rel Volume0.10 Prev Close4.06
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume31.94K Price4.04
Recom- SMA20-1.95% SMA50-6.43% SMA200-19.00% Volume1,554 Change-0.49%
Aug-31-23 06:30AM
May-26-23 04:40PM
Apr-18-23 06:30AM
Jan-17-23 08:20AM
Dec-27-22 05:44PM
04:53PM Loading…
Nov-17-22 04:53PM
Nov-08-22 04:30PM
Oct-14-22 04:01PM
Oct-04-22 08:50AM
Jul-24-22 08:41AM
Jun-02-22 04:30PM
May-17-22 11:34AM
May-16-22 04:10PM
Apr-27-22 04:45PM
05:49PM Loading…
Apr-20-22 05:49PM
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BUCHI J KEVINDirectorJun 09Buy0.2921,8586,284146,858Jun 13 12:07 PM
BUCHI J KEVINDirectorJun 08Buy0.3025,0007,400125,000Jun 09 02:26 PM
MARTINO MICHAEL ACEOMay 24Buy0.2976,89022,12176,890May 26 01:30 PM
BUCHI J KEVINDirectorMay 16Buy0.2732,5348,924100,000May 17 04:25 PM
BUCHI J KEVINDirectorMay 15Buy0.2544,02610,85767,466May 16 03:30 PM
Stevens David RDirectorMay 12Buy0.2245,0009,900103,971May 12 05:26 PM
BUCHI J KEVINDirectorMay 12Buy0.2423,4405,51323,440May 16 03:30 PM
Stevens David RDirectorMay 11Buy0.2250,00010,87558,971May 12 05:26 PM